Oppenheimer Reiterates Perform Rating, $94 Price Target on BioMarin Pharmaceutical (BMRN) on Positive CHMP Opinion for Roctavian
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated a Perform rating and $94.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), following Friday's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
